

Mariana Bastos-Oreiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6908209/publications.pdf>

Version: 2024-02-01

61
papers

528
citations

840776

11
h-index

752698

20
g-index

68
all docs

68
docs citations

68
times ranked

1122
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility. <i>International Journal of Hematology</i> , 2022, 115, 61-68.	1.6	8
2	Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05209.	0.5	13
3	Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain. <i>Cancers</i> , 2022, 14, 538.	3.7	4
4	Clinical grade production of α 1.5 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. <i>Transfusion</i> , 2022, 62, 374-385.	1.6	2
5	POSA57 Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2022, 25, S44.	0.3	0
6	Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. <i>Leukemia and Lymphoma</i> , 2022, 63, 1993-1996.	1.3	2
7	Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study. <i>Haematologica</i> , 2022, 107, 2675-2684.	3.5	11
8	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. <i>Leukemia and Lymphoma</i> , 2022, 63, 2063-2073.	1.3	9
9	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. <i>Cancers</i> , 2022, 14, 2673.	3.7	4
10	Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 992-996.	2.4	3
11	COMP versus CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥ 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. <i>Cancer Medicine</i> , 2021, 10, 1314-1326.	2.8	13
12	Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. <i>HemaSphere</i> , 2021, 5, e538.	2.7	52
13	Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 493.e1-493.e8.	1.2	5
14	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1919-1928.	2.4	13
15	Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 7512-7512.	1.6	7
16	Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. <i>Cancers</i> , 2021, 13, 3001.	3.7	2
17	Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition. <i>Molecular Oncology</i> , 2021, 15, 2273-2284.	4.6	5
18	Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	1.5	1

#	ARTICLE	IF	CITATIONS
19	Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. <i>Cancer Medicine</i> , 2021, 10, 7629-7640.	2.8	13
20	Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. <i>Cancer Medicine</i> , 2021, 10, 7585-7592.	2.8	7
21	Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo. <i>Blood</i> , 2021, 138, 2497-2497.	1.4	0
22	Real-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study. <i>Blood</i> , 2021, 138, 3850-3850.	1.4	0
23	Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 2827-2827.	1.4	2
24	Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 5	1.4	0
25	Cell-Free DNA Dynamic Concentration, CRP and LDH Pre-Infusion Are Predictors of Early Progression after CAR T-Cell Therapy in DLBCL Patients. <i>Blood</i> , 2021, 138, 1761-1761.	1.4	0
26	Dynamics and Management of CAR-T Cells Associated Cytopenias: A Single-Center Experience. <i>Blood</i> , 2021, 138, 4837-4837.	1.4	1
27	Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma. <i>Scientific Reports</i> , 2021, 11, 22815.	3.3	6
28	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203). <i>Blood</i> , 2021, 138, 813-813.	1.4	7
29	Impact of the Use of Bendamustine Immediately before the Collection of Hematopoietic Stem Cells in Lymphoma. a Study By the Geltamo Group. <i>Blood</i> , 2021, 138, 1771-1771.	1.4	1
30	Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain. <i>Blood</i> , 2021, 138, 1742-1742.	1.4	1
31	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020, 104, 400-408.	2.2	3
32	New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). <i>British Journal of Haematology</i> , 2020, 188, 888-897.	2.5	40
33	Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1716-1725.	2.4	2
34	RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. <i>Annals of Hematology</i> , 2020, 99, 799-808.	1.8	21
35	A VALIDATION, WITH NEW CLINICAL APPLICABILITY, OF A CLINICAL-GENETIC RISK MODEL THAT PREDICTS THROMBOSIS WITH HIGH SENSITIVITY IN PATIENTS WITH LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 534-534.	1.7	1
36	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. <i>Cancers</i> , 2019, 11, 1364.	3.7	23

#	ARTICLE	IF	CITATIONS
37	Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 82.	2.7	21
38	Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma. <i>Blood</i> , 2019, 134, 2807-2807.	1.4	6
39	Methotrexate-Induced Subacute Neurotoxicity Surrounding an Ommaya Reservoir in a Patient with Lymphoma. <i>American Journal of Case Reports</i> , 2019, 20, 1002-1005.	0.8	3
40	Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes. <i>Blood</i> , 2019, 134, 5216-5216.	1.4	0
41	Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime. <i>Blood</i> , 2019, 134, 3325-3325.	1.4	0
42	Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous) Tj ETQq0 0.0 rgBT /Overlock 10	0.4	0
43	Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients. <i>Blood</i> , 2019, 134, 2584-2584.	1.4	1
44	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1522-1531.	2.4	22
45	CD3+ Graft Cell Count Predicts Chronic Gvhd Incidence in Haploidentical Allogeneic Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S297.	2.0	0
46	Busulfanâ€based myeloablative conditioning regimens for haploidentical transplantation in highâ€risk acute leukemias and myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2018, 101, 332-339.	2.2	11
47	New Prognosis Score Including Absolute Lymphocytes/Monocytes Ratio and Beta2microglobulin in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). <i>Blood</i> , 2018, 132, 347-347.	1.4	1
48	Validation of the <sc>NCCN</sc>â€<sc>IPI</sc> for diffuse large Bâ€cell lymphoma (<sc>DLBCL</sc>): the addition of I ² ₂â€microglobulin yields a more accurate <sc>GELTAMO</sc>â€<sc>IPI</sc>. <i>British Journal of Haematology</i> , 2017, 176, 918-928.	2.5	65
49	A PROSPECTIVE STUDY TO EVALUATE THE UTILITY OF GERIATRIC ASSESSMENT AND INTERVENTION IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN A TERTIARY HOSPITAL. <i>Hematological Oncology</i> , 2017, 35, 417-418.	1.7	2
50	Inhibitory killer cell immunoglobulinâ€like receptor (<sc>iKIR</sc>) mismatches improve survival after Tâ€cellâ€repleted haploidentical transplantation. <i>European Journal of Haematology</i> , 2016, 96, 483-491.	2.2	15
51	Infectious Complications and Mortality after Autologous Stem Cell Transplantation for Lymphomas: A Comparison Between HIV-Infected and HIV-Negative Patients. <i>Blood</i> , 2016, 128, 2258-2258.	1.4	4
52	Myeloablative Conditioning Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PTCy) As GvHD Prophylaxis in High Risk Leukemias/Myelodysplastic Syndromes (MDS): Geth Experience. <i>Blood</i> , 2016, 128, 4690-4690.	1.4	2
53	Role of Cell Source and Graft Composition in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016, 128, 4664-4664.	1.4	0
54	Evaluation of Donor KIR2DL1 Allelic Polymorphism in the Setting of T-Cell Repleted Haploidentical Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S327.	2.0	0

#	ARTICLE	IF	CITATIONS
55	Influence of CD34+ and CD3+ Graft Content on Gvhd Development after Haploidentical Allogeneic Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2015, 126, 3131-3131.	1.4	0
56	Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project. <i>Blood</i> , 2015, 126, 3955-3955.	1.4	0
57	Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 239-246.	2.2	60
58	Differences in Natural Killer(NK) Reconstitution Between Unmanipulated Haploidentical and HLA Identical Stem Cell Transplantation and Relationship with Citomegalovirus and Graft Versus Host Disease (GVHD). Experience in One Centre in 22 Patients.. <i>Blood</i> , 2014, 124, 5872-5872.	1.4	0
59	Mismatches In Killer Immunoglobulin Receptor (KIR) Ligands and Inhibitory KIR Receptors Between Donor and Recipients Improve Survival After Non T Cell Depleted Haploidentical Transplantation. <i>Blood</i> , 2013, 122, 2009-2009.	1.4	0
60	Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease. <i>Bone Marrow Transplantation</i> , 2012, 47, 1241-1242.	2.4	15
61	Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	13